The J&J spinout and Neutrogena and Aveeno owner says the challenge facing its Skin Health and Beauty business is not about brand equity or online performance as much as in-store in the US, where it has underperformed. CEO Thibaut Mongon outlined planned investments, expected to drive growth acceleration in Kenvue’s fiscal 2024 second half, at the CAGNY 2024 conference.
Kenvue, Inc. leadership unpacked plans on 23 February that will reveal “a very different Kenvue” in 2024 compared with 2023, which marked its separation from Johnson & Johnson and launch as a standalone public company.
“This huge separation, entangling 135 years of history, went smoothly without any material impact on the business. But now we...